| 罗格列酮对2型糖尿病患者血清C反应蛋白和脂联素的影响 |
| |
| 引用本文： | 任冬梅. 罗格列酮对2型糖尿病患者血清C反应蛋白和脂联素的影响[J]. 解放军保健医学杂志, 2010, 0(1): 42-44 |
| |
| 作者姓名： | 任冬梅 |
| |
| 作者单位： | 解放军88医院内分泌科; |
| |
| 摘 要： | 目的观察罗格列酮对2型糖尿病（T2DM）患者血清C反应蛋白（CRP）和脂联素（AN）的影响。方法86例T2DM患者随机分为罗格列酮联合诺和灵30R组（观察组）41例和诺和灵30R组（对照组）45例,两组均于早餐、晚餐前30min各皮下注射1次诺和灵30R;观察组在诺和灵30R治疗的基础上,早餐前口服罗格列酮4mg。两组分别于治疗前、治疗后2个月检测患者空腹血糖（FPG）、餐后2h血糖（2hPG）、糖化血红蛋白（HbAlc）、血脂、AN及CRP水平,并计算诺和灵30R日剂量。结果两组患者治疗后FPG、2hPG及HbAlc均较治疗前明显下降（P〈0.01）;观察组治疗后CRP（4.10±0.53mg/L）、甘油三酯（1.84±0.20mmol/L）较治疗前（6.80±0.57mg/L,2.31±0.73mmol/L）明显下降（P〈0.05）,AN（2.45±3.00mg/L）较治疗前（1.03±1.28mg/L）明显升高（P〈0.05）,而对照组CRP、TG、AN治疗前后变化差异无统计学意义（P〉0.05）;观察组诺和灵30R日剂量（30.5±13.6U/d）较对照组（55.7±14.7U/d）明显减少（P〈0.01）。结论罗格列酮可降低T2DM患者CRP水平并提高AN水平,从而改善胰岛素抵抗,增强胰岛素的治疗效果。
|
| 关 键 词： | 糖尿病 罗格列酮 胰岛素抵抗 脂联素 C反应蛋白 |
The effect of rosiglitazone on serum adiponectin and C-reactive protein in Type 2 Diabetes Mellitus |
| |
| REN Dong-mei. The effect of rosiglitazone on serum adiponectin and C-reactive protein in Type 2 Diabetes Mellitus[J]. Journal Of Health Care And Medicine in Chinese Pla, 2010, 0(1): 42-44 |
| |
| Authors: | REN Dong-mei |
| |
| Affiliation: | Department of Endocrinology;The 88th Hospital;Taian 271000 China |
| |
| Abstract: | Objective To observe the effect of rosiglitazone on serum adiponectin and C-reactive protein in Type 2 Diabetes Mellitus(T2DM).Methods Eighty six patients with T2DM were randomly divided into Novolin 30R plus rosiglitazone group(n=41)and Novolin 30R group(n=45).Novolin was injected subcutaneously 30 minutes before breakfast and supper for Novolin group,while Novolin 30R plus rosiglitazone group was treated with rosiglitazone(4mg)before breakfast coupled with novolin 30R injection.Fasting blood glucose(FBG),... |
| |
| Keywords: | Diabetes Mellitus Rosiglitazone Insulin resistance Adiponectin C-reactive protein |
| 本文献已被 CNKI 维普 等数据库收录！ |
